AQR Capital Management
NGNE icon

AQR Capital Management’s Neurogene NGNE Stock Holding History

AQR Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$208K Buy
+10,311
New +$200K ﹤0.01% 3587
2021
Q1 		– Sell
-1,188
Closed -$335K – 2245
2020
Q4 		$335K Sell
1,188
-252
-18% -$61.6K ﹤0.01% 1927
2020
Q3 		$346K Buy
+1,440
New +$349K ﹤0.01% 1869

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

AQR Capital Management's NGNE Position: Q1 2026 in Review

AQR Capital Management opened a new position in Neurogene (NGNE) in Q1 2026: 10,311 shares worth $208K. The stake represents ﹤0.01% of the portfolio and ranks #3587 among its holdings. This is a return to the name: AQR Capital Management previously reported a position in NGNE as recently as Q4 2020.

AQR Capital Management first reported a position in NGNE in Q3 2020 and has held it in 3 quarters since. The position peaked at $346K in Q3 2020. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • AQR Capital Management held 10,311 shares of Neurogene worth $208K as of Q1 2026.
  • Neurogene was a new AQR Capital Management position in Q1 2026.
  • Neurogene made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #3587 holding.
  • AQR Capital Management first reported a position in Neurogene in Q3 2020 and has held it in 3 quarters since.
  • AQR Capital Management's Neurogene position peaked at $346K in Q3 2020.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.